期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 21, 期 7, 页码 1155-1166出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2015.03.002
关键词
Multiple myeloma; Transplantation; Recommendations; Guidelines
资金
- Celgene
- Onyx
- Millenium/Takeda
- Sanofi
- Celegene
- Janssen
- Millenium
- Otsuka
- Celegne
Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this evidence-based review, we have critically analyzed the data from the most recent clinical trials to better understand how to incorporate HCT and when HCT is indicated. We have provided our recommendations based on Strength of evidence with the knowledge that ongoing clinical trials make this a dynamic field. Within this document, we discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM. (C) 2015 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据